T Regulatory Cells(Stanford University)(T Regulatory Cells(Stanford University)) - 在研适应症：急性白血病，急性淋巴细胞白血病，急性髓性白血病_专利_临床

概要

基本信息

药物类型

Tregs细胞疗法

别名-

靶点-

作用方式

调节剂

作用机制

免疫调节剂

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病

在研适应症

急性白血病急性淋巴细胞白血病急性髓性白血病+ [4]

非在研适应症

慢性移植物抗宿主病类固醇难治性移植物抗宿主病

原研机构

Stanford University

在研机构

Stanford University

非在研机构-

权益机构-

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 T Regulatory Cells(Stanford University) 相关的临床试验

NCT01911039

/ Completed临床1期IIT

A Phase 1 Safety and Tolerability Study of Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic Graft Versus Host Disease

Chronic graft versus host disease (cGVHD) is a common complication of bone marrow or hematopoietic cell transplant from another person (allogeneic transplant). This study will determine if subjects with steroid dependent/refractory cGVHD can tolerate infusion of donor regulatory T cells and whether their cGVHD responds to the infusion.

开始日期2013-07-01

申办/合作机构

Stanford University

[+1]

NCT01660607

/ Completed临床1/2期IIT

Phase 1-2 Trial for Patients With Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT With a T-cell Depleted Graft With Infusion of Conventional T-cells and Regulatory T-cells

This study looks at giving specific types of immune cells, called regulatory T cells and conventional T cells, to patients with blood cancers who are receiving a stem cell transplant. These cells are added back to help the immune system recover and reduce complications after the transplant.

开始日期2012-02-09

申办/合作机构

Stanford University

[+2]

NCT01050764

/ Terminated临床1/2期IIT

A Feasibility Trial of Post-Transplant Infusion of Allogeneic Regulatory T Cells and Allogeneic Conventional T Cells in Patients With Hematologic Malignancies Undergoing Allogeneic Myeloablative Hematopoietic Cell Transplantation From Haploidentical-Related Donors

Patients with hematologic malignancies will receive myeloablative chemotherapy followed by stem cell rescue with bone marrow or hematopoietic peripheral blood stem cells collected by apheresis from a filgrastim- (G-CSF)-mobilized haploidentical related-donor, ie, hematopoietic peripheral blood stem cell transplant (HSCT).

开始日期2009-06-01

申办/合作机构

Stanford University

[+1]

100 项与 T Regulatory Cells(Stanford University) 相关的临床结果

登录后查看更多信息

100 项与 T Regulatory Cells(Stanford University) 相关的转化医学

登录后查看更多信息

100 项与 T Regulatory Cells(Stanford University) 相关的专利（医药）

登录后查看更多信息

100 项与 T Regulatory Cells(Stanford University) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性白血病	临床2期	美国	Stanford University	2012-02-09
急性淋巴细胞白血病	临床2期	美国	Stanford University	2012-02-09
急性髓性白血病	临床2期	美国	Stanford University	2012-02-09
加速期慢性骨髄性白血病	临床2期	美国	Stanford University	2012-02-09
慢性期慢性髓性白血病	临床2期	美国	Stanford University	2012-02-09
骨髓增生异常综合征	临床2期	美国	Stanford University	2012-02-09
非霍奇金淋巴瘤	临床2期	美国	Stanford University	2012-02-09
慢性移植物抗宿主病	临床1期	美国	Stanford University	2013-07-01
类固醇难治性移植物抗宿主病	临床1期	美国	Stanford University	2013-07-01